Published in Cochrane Database Syst Rev on January 23, 2008
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ (2010) 4.92
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases. Osteoporos Int (2009) 1.70
Exercise for improving outcomes after osteoporotic vertebral fracture. Cochrane Database Syst Rev (2013) 1.63
Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int (2009) 1.50
Digital X-ray radiogrammetry of hand or wrist radiographs can predict hip fracture risk--a study in 5,420 women and 2,837 men. Eur Radiol (2012) 1.49
Baseline age and time to major fracture in younger postmenopausal women. Menopause (2015) 1.49
The epidemiology of distal radius fractures. Hand Clin (2012) 1.40
Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study. BMC Musculoskelet Disord (2011) 1.37
Individualizing osteoporosis therapy. Osteoporos Int (2012) 1.15
Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ (2009) 1.12
Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop (2015) 1.11
Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int (2010) 1.09
Dietary patterns and incident low-trauma fractures in postmenopausal women and men aged ≥ 50 y: a population-based cohort study. Am J Clin Nutr (2010) 1.06
Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice. Bone (2011) 1.06
Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol (2011) 1.04
Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis (2012) 1.02
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int (2010) 0.98
Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord (2009) 0.98
Emerging therapies for the treatment of osteoporosis. J Midlife Health (2013) 0.93
The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab (2014) 0.93
Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Transl Med (2013) 0.92
Current, new and future treatments of osteoporosis. Rheumatol Int (2010) 0.92
Statins and hip fracture prevention--a population based cohort study in women. PLoS One (2012) 0.90
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. Ther Clin Risk Manag (2012) 0.90
Management of osteoporosis among home health and long-term care patients with a prior fracture. South Med J (2009) 0.89
Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporos Int (2013) 0.87
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int (2015) 0.85
Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr (2009) 0.84
Fracture prevention in postmenopausal women. BMJ Clin Evid (2011) 0.84
Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation setting. Aging Clin Exp Res (2010) 0.83
Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int (2009) 0.83
Comparing tolerability and efficacy of generic versus brand alendronate: a randomized clinical study in postmenopausal women with a recent fracture. PLoS One (2013) 0.83
Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial. J Bone Miner Metab (2014) 0.82
Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture. Osteoporos Int (2015) 0.82
Patterns of Prescription Drug Use Before and After Fragility Fracture. JAMA Intern Med (2016) 0.81
Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence. Ther Adv Musculoskelet Dis (2013) 0.81
Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures: evidence from the AIFA-BEST observational study. Eur J Clin Pharmacol (2014) 0.80
Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial. J Bone Miner Metab (2009) 0.78
The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug. Biomed Res Int (2014) 0.78
Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int (2017) 0.77
Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers? Osteoporos Int (2009) 0.77
Combined vertebral fracture assessment and bone mineral density measurement: a patient-friendly new tool with an important impact on the Canadian Risk Fracture Classification. Can Assoc Radiol J (2010) 0.77
Surgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature review. Clin Cases Miner Bone Metab (2016) 0.76
Medical treatment of osteoporotic vertebral fractures. Ther Adv Musculoskelet Dis (2011) 0.76
Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporos Int (2010) 0.76
Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study. J Bone Miner Metab (2010) 0.76
Partnership for fragility bone fracture care provision and prevention program (P4Bones): study protocol for a secondary fracture prevention pragmatic controlled trial. Implement Sci (2013) 0.76
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Clin Interv Aging (2009) 0.76
BMD screening in older women: initial measurement and testing interval. J Bone Miner Res (2012) 0.76
Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application. Medscape J Med (2009) 0.76
Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation. Int J Womens Health (2012) 0.76
Effect of risedronate on speed of sound in postmenopausal women with osteoporosis. World J Orthop (2013) 0.75
Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer's disease - exposure-matched cohort study. BMC Geriatr (2016) 0.75
Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study. PLoS One (2015) 0.75
Osteoporosis guidelines miss big picture. CMAJ (2011) 0.75
Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan. Osteoporos Int (2014) 0.75
Improving the osteoporosis care gap in elderly patients following hip fractures: For the ICHIBAN initiative. J Orthop (2013) 0.75
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy. Curr Osteoporos Rep (2012) 0.75
New strategies for osteoporosis patients previously managed with strontium ranelate. Ther Adv Musculoskelet Dis (2014) 0.75
Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis. J Bone Metab (2017) 0.75
Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks? Ther Adv Musculoskelet Dis (2015) 0.75
Bisphosphonates and atypical subtrochanteric fractures of the femur. Bone Joint Res (2017) 0.75
The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis. J Bone Metab (2017) 0.75
Bone Density Screening and Re-screening in Postmenopausal Women and Older Men. Curr Osteoporos Rep (2015) 0.75
Mechanism and Treatment Strategy of Osteoporosis after Transplantation. Int J Endocrinol (2015) 0.75
Bisphosphonates: forever or 5 years and stop? Can Fam Physician (2015) 0.75
The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton. PLoS One (2014) 0.75
Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis. Clin Med Insights Arthritis Musculoskelet Disord (2012) 0.75
Preservation and promotion of bone formation in the mandible as a response to a novel calcium-phosphate based biomaterial in mineral deficiency induced low bone mass male versus female rats. J Biomed Mater Res A (2016) 0.75
Treatment of osteoporosis after alendronate or risedronate. Osteoporos Int (2015) 0.75
Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. Osteoporos Int (2017) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum (1990) 27.50
Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA (1998) 23.39
Alignment of whole genomes. Nucleic Acids Res (1999) 20.02
Validation of a combined comorbidity index. J Clin Epidemiol (1994) 19.43
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet (1998) 19.31
Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature (1997) 19.08
A controlled trial of teaching critical appraisal of the clinical literature to medical students. JAMA (1987) 14.20
Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 12.21
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage (2008) 10.99
Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials (1995) 9.85
Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol (2002) 8.88
Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res (2000) 8.69
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Complete genome sequence and comparative analysis of the metabolically versatile Pseudomonas putida KT2440. Environ Microbiol (2002) 8.11
Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science (1998) 7.96
A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi. Mol Microbiol (2000) 7.60
OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage (2010) 7.52
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc (1998) 6.21
Effects of high levels of DNA adenine methylation on methyl-directed mismatch repair in Escherichia coli. Genetics (1983) 5.43
A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. Patient Educ Couns (1998) 5.40
The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature (1998) 5.16
Problems in the handling of clinical and research evidence by medical practitioners. Arch Intern Med (1983) 5.16
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol (1997) 5.09
Prevalence of AIDS-related risk factors and condom use in the United States. Science (1992) 5.05
A critical appraisal of the efficacy of continuing medical education. JAMA (1984) 4.95
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA (1998) 4.73
Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA (1994) 4.49
Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess (1999) 4.45
Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol (1993) 4.39
OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage (2007) 4.34
Genome sequence of Chlamydophila caviae (Chlamydia psittaci GPIC): examining the role of niche-specific genes in the evolution of the Chlamydiaceae. Nucleic Acids Res (2003) 4.33
Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet (2000) 4.16
Microbial genes in the human genome: lateral transfer or gene loss? Science (2001) 3.87
HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. JAMA (1994) 3.80
The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol (1998) 3.75
Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med (1968) 3.72
Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev (2006) 3.65
Rapid bacteriological diagnosis of pyogenic meningitis by latex agglutination. Lancet (1974) 3.64
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 3.45
Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr (1999) 3.45
CODIS STR loci data from 41 sample populations. J Forensic Sci (2001) 3.43
Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care (1996) 3.37
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol (1994) 3.32
The Ottawa patient decision aids. Eff Clin Pract (1999) 3.22
Raised ESR in polymyalgia rheumatica no longer a sine qua non? Lancet (1996) 3.20
Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. Med Decis Making (1998) 3.18
The MACTAR Patient Preference Disability Questionnaire--an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol (1987) 3.13
Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev (2005) 3.00
The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis (1985) 2.96
Costs and benefits of routine follow-up after curative treatment for endometrial cancer. CMAJ (1997) 2.93
NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci (2000) 2.87
The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am (1993) 2.85
Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol (1998) 2.77
Pneumococcal antigen in lobar pneumonia. J Clin Pathol (1975) 2.75
Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum (2006) 2.73
Condom use in multi-ethnic neighborhoods of San Francisco: the population-based AMEN (AIDS in Multi-Ethnic Neighborhoods) Study. Am J Public Health (1992) 2.71
Effect of acetylsalicylic acid, other nonsteroidal anti-inflammatory agents, and dipyridamole on human blood platelets. J Lab Clin Med (1970) 2.69
Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev (2002) 2.65
Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev (2006) 2.59
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol (1990) 2.50
Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med (1997) 2.48
The International Clinical Epidemiology Network (INCLEN): a progress report. J Clin Epidemiol (1991) 2.32
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Setting educational priorities for learning the concepts of population health. Med Educ (1989) 2.19
Sequence and analysis of chromosome 3 of the plant Arabidopsis thaliana. Nature (2000) 2.17
Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol (1993) 2.14
A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage (2002) 2.14
Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumatol (1983) 2.13
In vivo cell sorting in complementary segmental domains mediated by Eph receptors and ephrins. Nature (1999) 2.09
Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev (2002) 2.01
Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum (2001) 1.96
Minimal clinically important differences: review of methods. J Rheumatol (2001) 1.94
A comparison of resident performance on real and simulated patients. J Med Educ (1982) 1.92
Knowledge and clinical problem-solving. Med Educ (1985) 1.91
A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthritis Cartilage (2002) 1.89
Influence of fine structure of lipid A on Limulus amebocyte lysate clotting and toxic activities. Infect Immun (1984) 1.89
School feeding for improving the physical and psychosocial health of disadvantaged elementary school children. Cochrane Database Syst Rev (2007) 1.88
Do silicone breast implants cause rheumatologic disorders? A systematic review for a court-appointed national science panel. Arthritis Rheum (2001) 1.88
The EphA4 and EphB1 receptor tyrosine kinases and ephrin-B2 ligand regulate targeted migration of branchial neural crest cells. Curr Biol (1997) 1.88
Assessing the quality of the DNA sequence from the Human Genome Project. Genome Res (1999) 1.87
Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci (1993) 1.87
Sequence and analysis of chromosome 1 of the plant Arabidopsis thaliana. Nature (2000) 1.85
Diagnosis of vertical HIV-1 transmission using the polymerase chain reaction and dried blood spot specimens. J Acquir Immune Defic Syndr (1992) 1.78